Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Audit MicroControls has updated its logo, mission statement, and social media campaign. Audit’s mission is to supply daily QC and calibration verification/linearity materials to clinical labs worldwide while providing support, real-time data-reduction tools, same-day shipping, and quality products at a fair price.
ViroStat offers two new sets of Monotope monoclonal antibodies to the major capsid protein of the GI and GII noroviruses. The new antibodies function in ELISA and lateral flow applications for rapid detection of these viruses.
Quest Diagnostics and Hologic have entered into a strategic alliance to more broadly offer testing based on Hologic’s Aptima family of products, as well as to co-develop and promote advanced diagnostic solutions to improve women’s health.
The FDA has approved a workflow process for Roche Diagnostics’ Cobas HPV test that allows sample processing from the primary sample collection vial after it has been used for cytology (Pap) testing. Labs can load the same vial used for a ThinPrep Pap test directly onto the Cobas 4800 system for high-risk HPV and individual HPV 16 and 18 genotype testing. The workflow option uses a special primary vial rack for the Cobas 4800. The Cobas HPV test, approved by
Biocare Medical’s Supernova antibodies contain a higher antibody concentration than standard predilutes. Clients now have the option of preserving limited tissue specimens while still providing multi-antigen identification in about the same time as an antibody cocktail. This is achieved using Supernova antibodies in sequential incubations combined with Biocare’s double stain detection. Unique cocktails can also be created with ease as Supernova antibodies have been prepared in optimal diluents for specific tissue types. Supernova antibodies require between 10- and 20-minute incubations.
Kreatech has signed an agreement with the Lung Cancer Mutation Consortium (LCMC) allowing LCMC study sites to use Kreatech’s Repeat-Free Poseidon fluorescent in situ hybridization (FISH) probes to help identify molecular (DNA) changes in study samples.
Saladax Biomedical has been certified as a registered CLIA laboratory by the Office of Clinical Standards and Quality, a part of CMS that regulates lab testing performed on humans. The CLIA certification and approval allows the company to begin clinical laboratory operations for its MyCare product portfolio at facilities in Bethlehem, Pa.
Siemens Healthcare Diagnostics has obtained FDA clearance to offer pleural fluid pH testing on its RapidPoint 500 blood gas system. The addition of pleural fluid pH testing to the RapidPoint 500 complements the analyzer’s critical care menu, which includes blood gas, electrolyte, glucose, lactate, and full CO-oximetry tests, including neonatal total bilirubin and total hemoglobin.
BG Medicine’s galectin-3 testing has been recognized in the 2013 American College of Cardiology Foundation and American Heart Association (ACCF/AHA) Guideline for the Management of Heart Failure, which is designed to assist clinicians in selecting the best management strategy for patients and provides analysis of prevention, diagnosis, risk stratification, and treatment data.
Thermo Fisher Scientific’s Orbitrap Fusion Tribrid liquid chromatography-mass spectrometry (LC-MS) system combines its quadrupole, Orbitrap, and linear ion trap mass analyzers in a “Tribrid” architecture that analyzes complex biological samples.
